A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Randomized Study to Investigate the Effect of Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2016
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 20 Apr 2016 Status changed from active, no longer recruiting to completed.
- 18 Aug 2015 Planned End Date changed from 1 Apr 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 16 Jun 2015 Planned End Date changed from 1 May 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.